ARCHIVES

Neratinib Graduates from I-SPY Phase II Adaptive Trial Regimen

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

NCI-Approved Clinical Trials

August 25, 2006

In Brief: Bernard Fisher Professorship Endowed By ICI Pharma; Brady wins RSNA Medal

January 12, 1990

Six Compounds Carcinogenic, Risk to Humans, CH Subgroup Finds

February 2, 1979

Multiple Studies Show Benefit of CTL019, A Personalized Therapy, in CLL and ALL

December 27, 2013

Data Presented At Scientific Meetings Can Have Impact On Patient Treatment

March 31, 2006

ACCC Seeks Greater Role In Clinical Research Priorities; Suggests Up To 400 Cancer Program

April 13, 1979